Stockscreener 앱 받기
11.03
4.95%
0.52
시간 외 거래:
11.09
0.06
+0.54%
전일 마감가:
$10.51
열려 있는:
$10.54
하루 거래량:
3.08M
Relative Volume:
3.49
시가총액:
$688.46M
수익:
-
순이익/손실:
$-106.81M
주가수익비율:
-3.3306
EPS:
-3.3117
순현금흐름:
$-8.40M
1주 성능:
+10.85%
1개월 성능:
+3.86%
6개월 성능:
-28.42%
1년 성능:
-33.43%
1일 변동 폭
$10.37
$11.43
1주일 범위
$9.06
$11.43
52주 변동 폭
$8.97
$30.96
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
11.03 | 688.46M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Immunome (NASDAQ:IMNM) Trading 7.2% HigherStill a Buy? - MarketBeat
Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering - StockTitan
Immunome announces $125 million stock offering - MSN
Immunome (NASDAQ:IMNM) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Vanguard Group Inc. Reduces Stake in Immunome Inc. - GuruFocus.com
Latham & Watkins Advises on Immunome’s Upsized Public Offering of Common Stock - Legal Desire News Network
Immunome stock tumbles after public offering pricing - MSN
Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha
Immunome stock tumbles after public offering pricing By Investing.com - Investing.com South Africa
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome Prices $150 Million Stock Offering -January 30, 2025 at 03:53 am EST - Marketscreener.com
JPMorgan Chase & Co. Acquires 1,520 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Announces Pricing of Upsized Public Offering of Common Stock - BioSpace
Immunome Announces Proposed Public Offering of Common Stock - BioSpace
Immunome's Massive $150M Capital Raise: Major Banks Back Biotech's Ambitious Plans - StockTitan
Immunome's Massive $125M Capital Raise Could Reshape Cancer Treatment Landscape - StockTitan
Immunome CFO receives relocation package, $400K in bonuses - MSN
Immunome (IMNM) Stock Price, News & Analysis - MarketBeat
Immunome CFO receives relocation package, $400K in bonuses By Investing.com - Investing.com Canada
Immunome CFO Relocation and Compensation Package Unveiled - TipRanks
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Magnus Financial Group LLC - MarketBeat
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2% - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap UpShould You Buy? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ:IMNM) Stock Price Down 7.1%Here's Why - MarketBeat
Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush - Defense World
Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush - MarketBeat
Immunome (NASDAQ:IMNM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Hummingbird Bioscience Licenses Novel Antibodies to Immunome - The Korea Bizwire
When the Price of (IMNM) Talks, People Listen - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short Interest - MarketBeat
Geode Capital Management LLC Has $17.66 Million Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Geode Capital Management LLC Increases Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Barclays PLC Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Shares Down 5.7%Time to Sell? - MarketBeat
State Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
State Street Corp Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):